Injectable MPL allergy vaccine - Allergy Therapeutics
Alternative Names: Birch MATA MPL; Birch pollen allergen extract; Birch pollen modified allergen tyrosine-absorbed; Grass MATA MPL; Grass pollen modified allergen tyrosine-adsorbed; Pollinex Quattro; Pollinex Quattro Grass; Pollinex Quattro Tree; Pollinex Quattro® Birch; PQ Birch; PQ Grass; Tree MATA MPLLatest Information Update: 18 Mar 2025
At a glance
- Originator Allergy Therapeutics
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Grass pollen hypersensitivity; Tree pollen hypersensitivity
- Preregistration Allergic rhinoconjunctivitis
- Phase II/III Seasonal allergic rhinitis
Most Recent Events
- 27 Nov 2024 Phase-III clinical trials in Allergic rhinoconjunctivitis (In children) (SC)
- 25 Nov 2024 Preregistration for Allergic rhinoconjunctivitis in Germany (SC)
- 24 Oct 2024 Efficacy and adverse events data from a phase III RESONATE trial in Allergic Rhinitis due to Grass Allergy presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2024)